Literature DB >> 26780545

Eradication of Blastocystis in humans: Really necessary for all?

Özgür Kurt1, Funda Doğruman Al2, Mehmet Tanyüksel3.   

Abstract

Blastocystis (initially named as Blastocystis hominis) has long been known as a protist without any clinical significance. However, there is now a huge pile of case reports where Blastocystis is blamed for the symptoms and the infection described in the patients. Introduction of the presence of as many as 17 Blastocystis subtypes while many infected individuals are non-symptomatic initially brought about the correlation between the subtypes and pathogenicity; however, the outcomes of these trials were not consistent and did not explain its pathogenicity. Today, it is mostly acknowledged that Blastocystis may colonize many individuals but the infection's onset depends on the interaction between the virulence of parasites and host's immune competence. Eradication of Blastocystis is essential in some cases where it is the only infectious agent and patient is suffering from some symptoms. In such cases, metronidazole is the drug of choice but its efficacy is relatively low in some cases. Other agents used include trimethoprim-sulfamethoxazole, paromomycin, and furazolidone. Recent studies on the interactions between human health and the role of gut microbiota introduces new data which may significantly change our point of view against some protists, which we tend to see as "parasites requiring urgent eradication for cure". May the presence or absence of some Blastocystis subtypes necessary for human health, or is the absence or presence of certain Blastocystis subtypes in human gut is associated with certain diseases/infections? The answers of these questions will surely guide us to select patients requiring treatment against Blastocystis infection in future.
Copyright © 2016. Published by Elsevier Ireland Ltd.

Entities:  

Keywords:  Blastocystis; Eradication; Metronidazole; Microbiota; Review; Treatment

Mesh:

Substances:

Year:  2016        PMID: 26780545     DOI: 10.1016/j.parint.2016.01.010

Source DB:  PubMed          Journal:  Parasitol Int        ISSN: 1383-5769            Impact factor:   2.230


  17 in total

1.  Development and evaluation of high-resolution melting curve analysis for rapid detection and subtyping of Blastocystis and comparison the results with sequencing.

Authors:  Hanieh Mohammad Rahimi; Hamed Mirjalali; Maryam Niyyati; Ali Haghighi; Hamid Asadzadeh Aghdaei; Mohammad Reza Zali
Journal:  Parasitol Res       Date:  2019-11-05       Impact factor: 2.289

2.  Exacerbated symptoms in Blastocystis sp.-infected patients treated with metronidazole: two case studies.

Authors:  Arutchelvan Rajamanikam; Suresh Kumar; Chandramathi Samudi; Madhav Kudva
Journal:  Parasitol Res       Date:  2018-06-05       Impact factor: 2.289

3.  Improvement in the detection of enteric protozoa from clinical stool samples using the automated urine sediment analyzer sediMAX® 2 compared to sediMAX® 1.

Authors:  J Intra; M R Sala; R Falbo; F Cappellini; P Brambilla
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-09-20       Impact factor: 3.267

4.  Evaluation of the effect of 1,3-bis-(4-phenyl-[1,2,3] triazole-1-il)2-propanol in comparison with metronidazole in an in vitro culture of Blastocystis in samples of patients with irritable bowel syndrome.

Authors:  L García-Flores; J G Santillán-Benítez; E Cuevas-Yáñez; P Caballero-Vásquez; S Zamudio-Chávez; E Morales-Ávila
Journal:  J Parasit Dis       Date:  2019-05-02

5.  Common intestinal parasitic infections among patients living in Riyadh, Saudi Arabia: Prevalence and demographic associations (A cross-sectional retrospective study).

Authors:  Yousra Eldaw Abdelkareem; Anwar H Abohashem; Ziad A Memish; Abdulwahab Z Binjomah; Fatima M Takroni; Hind S Al-Amoudi; Ashwaq H Masluf; Saad M Alsurayea; Nader Alharbi; Ibrahim M Aldealej
Journal:  Ann Med Surg (Lond)       Date:  2022-04-28

6.  Blastocystis in Côte d'Ivoire: molecular identification and epidemiological data.

Authors:  R D'Alfonso; M Santoro; D Essi; A Monsia; Y Kaboré; C Glé; D Di Cave; R P Sorge; V Di Cristanziano; F Berrilli
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-07-04       Impact factor: 3.267

7.  Viability Screen of LOPAC1280 Reveals Phosphorylation Inhibitor Auranofin as a Potent Inhibitor of Blastocystis Subtype 1, 4, and 7 Isolates.

Authors:  John Anthony Yason; Kristine Anne Ru Ping Koh; Kevin Shyong Wei Tan
Journal:  Antimicrob Agents Chemother       Date:  2018-07-27       Impact factor: 5.191

Review 8.  Blastocystis: how do specific diets and human gut microbiota affect its development and pathogenicity?

Authors:  M Lepczyńska; J Białkowska; E Dzika; K Piskorz-Ogórek; J Korycińska
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-03-22       Impact factor: 3.267

9.  Resistance towards metronidazole in Blastocystis sp.: A pathogenic consequence.

Authors:  Arutchelvan Rajamanikam; Ho Shiaw Hooi; Madhav Kudva; Chandramathi Samudi; Suresh Kumar
Journal:  PLoS One       Date:  2019-02-22       Impact factor: 3.240

10.  Two-day enema antibiotic therapy for parasite eradication and resolution of symptoms.

Authors:  Niloufar Roshan; Annabel Clancy; Anoja W Gunaratne; Antoinette LeBusque; Denise Pilarinos; Thomas J Borody
Journal:  World J Gastroenterol       Date:  2020-07-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.